PayamNahidMD
Pulmonology • San Francisco, CACritical Care Medicine, Pleural Disease
Associate Professor, Medicine, UCSF School of Medicine
Are you Dr. Nahid?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1001 Potrero Ave
5k1
San Francisco, CA 94110Phone+1 415-206-8313Fax+1 415-695-1551
Summary
- Dr. Payam Nahid, MD is a pulmonologist in San Francisco, California. He is currently licensed to practice medicine in California. He is an Associate Professor at UCSF School of Medicine.
Education & Training
University of California, Irvine, School of MedicineClass of 1997
Certifications & Licensure
CA State Medical License 1999 - 2026
American Board of Internal Medicine Critical Care Medicine- American Board of Internal Medicine Pulmonary Disease
Publications & Presentations
PubMed
- C-Reactive Protein-based Screening of People with Tuberculosis Symptoms: A Diagnostic Accuracy Study.Brigitta Derendinger, Tessa K Mochizuki, Danaida Marcelo, Deepa Shankar, Wilson Mangeni
American Journal of Respiratory and Critical Care Medicine. 2025-03-01 - Safety and Tolerability of a Short Course of Linezolid for the Treatment of Predominantly Moderate to Severe Tuberculous Meningitis in Adults with HIV.Felicia C Chow, Paddy Kafeero, Patrick Muhumuza, Maria Nakimbugwe, Anthony Ssemaganda
The Journal of Infectious Diseases. 2025-02-17 - 2 citationsOral Regimens for Rifampin-Resistant, Fluoroquinolone-Susceptible Tuberculosis.Lorenzo Guglielmetti, Uzma Khan, Gustavo E Velásquez, Maelenn Gouillou, Amanzhan Abubakirov
The New England Journal of Medicine. 2025-01-30
Press Mentions
The Fight Against TB Was Frozen in Time, Until Now. See Its FutureMarch 4th, 2025- UCSF Joins $200 Million Global Tuberculosis ConsortiumAugust 2nd, 2022
- Study: Four-Month Regimen of Anti-TB Drugs Works Just as Well as Standard RegimenMay 24th, 2021
- Join now to see all
Grant Support
- UCSF-UCB Tuberculosis Research Advancement Center (TRAC)UNIVERSITY OF CALIFORNIA, SAN FRANCISCO2022–2027
- DRAMATIC Phase 2 Duration Randomized MDR-TB Treatment TrialUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2020–2026
- C3PO - The Candidate Clinical Correlate of Prognostic Outcome for TB StudyUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2024–2025
- C3PO - The Candidate Clinical Correlate of Prognostic Outcome for TB StudyUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2024–2025
- C3PO - The Candidate Clinical Correlate of Prognostic Outcome for TB StudyUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2024–2025
- C3PO - The Candidate Clinical Correlate of Prognostic Outcome for TB StudyUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2024–2025
- C3PO - The Candidate Clinical Correlate of Prognostic Outcome for TB StudyUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2024–2025
- TB Research And Mentorship Program (TB RAMP)UNIVERSITY OF CALIFORNIA, SAN FRANCISCO2020–2025
- TB Research And Mentorship Program (TB RAMP)UNIVERSITY OF CALIFORNIA, SAN FRANCISCO2020–2025
- TB Research And Mentorship Program (TB RAMP)UNIVERSITY OF CALIFORNIA, SAN FRANCISCO2020–2025
- TB Research And Mentorship Program (TB RAMP)UNIVERSITY OF CALIFORNIA, SAN FRANCISCO2020–2025
- Rapid Research for Diagnostics Development in TB Network (R2D2 TB Network)UNIVERSITY OF CALIFORNIA, SAN FRANCISCO2020–2025
